Lege Artis Medicinae

[Tonsillectomy]

GERLINGER Imre

APRIL 22, 2008

Lege Artis Medicinae - 2008;18(04)

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Pain and Pain Relief in Rheumatology]

GAÁL János

Lege Artis Medicinae

[The Patient’s Culture]

dr. BÁNFALVI Attila

Lege Artis Medicinae

[RECENT ADVANCEMENTS IN THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION]

SERES András István

[Age-related macular degeneration is the leading cause of blindness in developed countries. In the last few years, new therapeutic approaches such as photodynamic therapy and intravitreal injections of vascular endothelial growth factor antagonists were introduced that do not only prevent disease progression but also give the hope of vision improvement. Of the new diagnostic methods, the use of optical coherence tomography improves diagnosis and also permits the qualitative measurement of therapeutic effects. Given the current high price of the new drugs and the need for frequent re-treatments, a significant increase in the economic burden of the disease is foreseeable.]

Lege Artis Medicinae

[The Flame shall be Protected! An Interview with Anatomist Professor Tibor Donáth by Elemér Nemesánszky]

dr. NEMESÁNSZKY Elemér

Lege Artis Medicinae

[Hereditary angioneurotic oedema]

FARKAS Henriette

All articles in the issue

Related contents

Hypertension and nephrology

[New development in the pathogenesis, diagnosis and treatment of IgA nephropathy]

NAGY Judit, VAS Tibor, KOVÁCS Tibor

[IgA nephropathy is one of the leading cause of primary glomerulonephritis worldwide. IgA nephropathy is regarded as an immune mediated disease with a multi-hit pathogenesis starting with the production of poorly glycosylated IgA1 and glycan-specific IgG and IgA autoantibodies leading to the formation of IgA1 containing immune complexes. These immune complexes deposit in the glomerular mesangium followed by the onset of mesangioproliferative glomerulonephritis. The disease has variable clinical presentation and outcome. There is a need to identify patients who have the potential to progress to end-stage renal disease with the help of clinical, histological and biological markers. Treatment options for IgA nephropathy are largely based on opinion or weak evidence. It is true for the KDIGO Clinical Practice Guideline for Glomerulonephritis treatment recommendations containing low level of evidence for almost all recommendations related to IgA nephropathy. It is suggested to separate the patients into 3 groups on the basis of risk to progression and to give not-specific supportive treatment (especially angiotensin converting enzyme inhibitors or angiotensin receptor blocking agents) to all of them on the basis of the risk factors. We discuss the recommendations of the KDIGO Guideline about steroid and immunosuppressive treatment for moderate and high risk patients. Lastly, we provide our perspective on the existing other treatment options (tonsillectomy etc.) and on ongoing clinical trials.]